Quarterly Report (10-q)
July 22 2022 - 2:43PM
Edgar (US Regulatory)
0001589150
false
--09-30
2022
Q3
0001589150
2021-10-01
2022-06-30
0001589150
2022-07-17
0001589150
2022-06-30
0001589150
2021-09-30
0001589150
us-gaap:SeriesAPreferredStockMember
2022-06-30
0001589150
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001589150
RGBP:SeriesAAPreferredStockMember
2022-06-30
0001589150
RGBP:SeriesAAPreferredStockMember
2021-09-30
0001589150
RGBP:SeriesMMember
2022-06-30
0001589150
RGBP:SeriesMMember
2021-09-30
0001589150
RGBP:SeriesNCMember
2022-06-30
0001589150
RGBP:SeriesNCMember
2021-09-30
0001589150
2022-04-01
2022-06-30
0001589150
2021-04-01
2021-06-30
0001589150
2020-10-01
2021-06-30
0001589150
RGBP:PreferredStockSeriesAMember
2020-09-30
0001589150
RGBP:SeriesAAPreferredStockMember
2020-09-30
0001589150
RGBP:SeriesNCPreferredStockMember
2020-09-30
0001589150
us-gaap:CommonStockMember
2020-09-30
0001589150
RGBP:SeriesMPreferredStockMember
2020-09-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2020-09-30
0001589150
us-gaap:RetainedEarningsMember
2020-09-30
0001589150
RGBP:ContributedCapitalMember
2020-09-30
0001589150
2020-09-30
0001589150
RGBP:PreferredStockSeriesAMember
2020-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2020-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2020-12-31
0001589150
us-gaap:CommonStockMember
2020-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2020-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001589150
us-gaap:RetainedEarningsMember
2020-12-31
0001589150
RGBP:ContributedCapitalMember
2020-12-31
0001589150
2020-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-03-31
0001589150
us-gaap:CommonStockMember
2021-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001589150
us-gaap:RetainedEarningsMember
2021-03-31
0001589150
RGBP:ContributedCapitalMember
2021-03-31
0001589150
2021-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-09-30
0001589150
RGBP:SeriesAAPreferredStockMember
2021-09-30
0001589150
RGBP:SeriesNCPreferredStockMember
2021-09-30
0001589150
us-gaap:CommonStockMember
2021-09-30
0001589150
RGBP:SeriesMPreferredStockMember
2021-09-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-09-30
0001589150
us-gaap:RetainedEarningsMember
2021-09-30
0001589150
RGBP:ContributedCapitalMember
2021-09-30
0001589150
RGBP:PreferredStockSeriesAMember
2021-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-12-31
0001589150
us-gaap:CommonStockMember
2021-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001589150
us-gaap:RetainedEarningsMember
2021-12-31
0001589150
RGBP:ContributedCapitalMember
2021-12-31
0001589150
2021-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2022-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2022-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2022-03-31
0001589150
us-gaap:CommonStockMember
2022-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2022-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001589150
us-gaap:RetainedEarningsMember
2022-03-31
0001589150
RGBP:ContributedCapitalMember
2022-03-31
0001589150
2022-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2020-10-01
2020-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2020-10-01
2020-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2020-10-01
2020-12-31
0001589150
us-gaap:CommonStockMember
2020-10-01
2020-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2020-10-01
2020-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2020-10-01
2020-12-31
0001589150
us-gaap:RetainedEarningsMember
2020-10-01
2020-12-31
0001589150
RGBP:ContributedCapitalMember
2020-10-01
2020-12-31
0001589150
2020-10-01
2020-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-01-01
2021-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-01-01
2021-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-01-01
2021-03-31
0001589150
us-gaap:CommonStockMember
2021-01-01
2021-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-01-01
2021-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-03-31
0001589150
us-gaap:RetainedEarningsMember
2021-01-01
2021-03-31
0001589150
RGBP:ContributedCapitalMember
2021-01-01
2021-03-31
0001589150
2021-01-01
2021-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2021-04-01
2021-06-30
0001589150
RGBP:SeriesAAPreferredStockMember
2021-04-01
2021-06-30
0001589150
RGBP:SeriesNCPreferredStockMember
2021-04-01
2021-06-30
0001589150
us-gaap:CommonStockMember
2021-04-01
2021-06-30
0001589150
RGBP:SeriesMPreferredStockMember
2021-04-01
2021-06-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2021-06-30
0001589150
us-gaap:RetainedEarningsMember
2021-04-01
2021-06-30
0001589150
RGBP:ContributedCapitalMember
2021-04-01
2021-06-30
0001589150
RGBP:PreferredStockSeriesAMember
2021-10-01
2021-12-31
0001589150
RGBP:SeriesAAPreferredStockMember
2021-10-01
2021-12-31
0001589150
RGBP:SeriesNCPreferredStockMember
2021-10-01
2021-12-31
0001589150
us-gaap:CommonStockMember
2021-10-01
2021-12-31
0001589150
RGBP:SeriesMPreferredStockMember
2021-10-01
2021-12-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-10-01
2021-12-31
0001589150
us-gaap:RetainedEarningsMember
2021-10-01
2021-12-31
0001589150
RGBP:ContributedCapitalMember
2021-10-01
2021-12-31
0001589150
2021-10-01
2021-12-31
0001589150
RGBP:PreferredStockSeriesAMember
2022-01-01
2022-03-31
0001589150
RGBP:SeriesAAPreferredStockMember
2022-01-01
2022-03-31
0001589150
RGBP:SeriesNCPreferredStockMember
2022-01-01
2022-03-31
0001589150
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001589150
RGBP:SeriesMPreferredStockMember
2022-01-01
2022-03-31
0001589150
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001589150
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001589150
RGBP:ContributedCapitalMember
2022-01-01
2022-03-31
0001589150
2022-01-01
2022-03-31
0001589150
RGBP:PreferredStockSeriesAMember
2022-04-01
2022-06-30
0001589150
RGBP:SeriesAAPreferredStockMember
2022-04-01
2022-06-30
0001589150
RGBP:SeriesNCPreferredStockMember
2022-04-01
2022-06-30
0001589150
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001589150
RGBP:SeriesMPreferredStockMember
2022-04-01
2022-06-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001589150
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001589150
RGBP:ContributedCapitalMember
2022-04-01
2022-06-30
0001589150
RGBP:PreferredStockSeriesAMember
2021-06-30
0001589150
RGBP:SeriesAAPreferredStockMember
2021-06-30
0001589150
RGBP:SeriesNCPreferredStockMember
2021-06-30
0001589150
us-gaap:CommonStockMember
2021-06-30
0001589150
RGBP:SeriesMPreferredStockMember
2021-06-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2021-06-30
0001589150
us-gaap:RetainedEarningsMember
2021-06-30
0001589150
RGBP:ContributedCapitalMember
2021-06-30
0001589150
2021-06-30
0001589150
RGBP:PreferredStockSeriesAMember
2022-06-30
0001589150
RGBP:SeriesAAPreferredStockMember
2022-06-30
0001589150
RGBP:SeriesNCPreferredStockMember
2022-06-30
0001589150
us-gaap:CommonStockMember
2022-06-30
0001589150
RGBP:SeriesMPreferredStockMember
2022-06-30
0001589150
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001589150
us-gaap:RetainedEarningsMember
2022-06-30
0001589150
RGBP:ContributedCapitalMember
2022-06-30
0001589150
srt:MinimumMember
2021-10-01
2022-06-30
0001589150
srt:MaximumMember
2021-10-01
2022-06-30
0001589150
2021-04-01
2022-06-30
0001589150
RGBP:ZanderTherapeuticsMember
2022-06-30
0001589150
2012-04-24
2022-06-30
0001589150
RGBP:DavidKoosMember
2022-06-30
0001589150
RGBP:DavidKoosMember
2022-06-30
0001589150
RGBP:DavidKoosMember
2021-10-01
2022-06-30
0001589150
RGBP:March82016Member
2022-06-30
0001589150
RGBP:April62016Member
2022-06-30
0001589150
RGBP:April62016Member
2022-06-20
0001589150
RGBP:October312016Member
2022-06-30
0001589150
RGBP:October3120161Member
2022-06-30
0001589150
RGBP:October3120162Member
2022-06-30
0001589150
RGBP:October3120162Member
2021-06-30
0001589150
RGBP:March132017Member
2022-06-30
0001589150
RGBP:March132017Member
2021-10-01
2022-06-30
0001589150
RGBP:March312017Member
2022-06-30
0001589150
RGBP:March3120171Member
2022-06-30
0001589150
RGBP:March3120171Member
2021-10-01
2022-06-30
0001589150
RGBP:April192017Member
2022-06-30
0001589150
RGBP:May52017Member
2022-06-30
0001589150
RGBP:May52017Member
2021-10-01
2022-06-30
0001589150
RGBP:June262017Member
2022-06-30
0001589150
RGBP:June262017Member
2021-10-01
2022-06-30
0001589150
RGBP:Sept252017Member
2022-06-30
0001589150
RGBP:Sept252017Member
2021-10-01
2022-06-30
0001589150
RGBP:Oct0317Member
2022-06-30
0001589150
RGBP:Oct0317Member
2021-10-01
2022-06-30
0001589150
RGBP:Oct1617Member
2022-06-30
0001589150
RGBP:Oct1617Member
2021-10-01
2022-06-30
0001589150
RGBP:Nov0117Member
2022-06-30
0001589150
RGBP:Nov0117Member
2021-10-01
2022-06-30
0001589150
RGBP:Nov0120172Member
2022-06-30
0001589150
RGBP:Nov0120172Member
2021-10-01
2022-06-30
0001589150
RGBP:Dec2017Member
2022-06-30
0001589150
RGBP:Dec2017Member
2021-10-01
2022-06-30
0001589150
RGBP:Feb2818Member
2022-06-30
0001589150
RGBP:Feb2818Member
2021-10-01
2022-06-30
0001589150
RGBP:July112018Member
2022-06-30
0001589150
RGBP:July112018Member
2021-10-01
2022-06-30
0001589150
RGBP:September302018Member
2022-06-30
0001589150
RGBP:September302018Member
2021-10-01
2022-06-30
0001589150
RGBP:July192019Member
2022-06-30
0001589150
RGBP:September172021Member
2022-06-30
0001589150
RGBP:September172021Member
2021-10-01
2022-06-30
0001589150
RGBP:March172022Member
2022-06-30
0001589150
RGBP:ZanderTherapeuticsMember
2019-05-30
2019-06-11
0001589150
RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember
2019-11-01
2019-11-29
0001589150
RGBP:ZanderTherapeuticsMember
2021-10-01
2022-06-30
0001589150
RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember
2021-10-01
2022-06-30
0001589150
us-gaap:CommonStockMember
RGBP:ZanderTherapeuticsMember
2022-06-30
0001589150
us-gaap:CommonStockMember
RGBP:ZanderTherapeuticsMember
2021-10-01
2022-06-30
0001589150
RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember
2022-06-30
0001589150
RGBP:UnrelatedPartyMember
2021-04-01
2021-06-30
0001589150
RGBP:UnrelatedPartyMember
2021-07-01
2021-09-30
0001589150
us-gaap:CommonStockMember
2022-06-30
0001589150
us-gaap:CommonStockMember
RGBP:OncologyPharmaMember
2022-06-30
0001589150
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-04-01
2022-04-05
0001589150
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-04-01
2022-04-08
0001589150
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-05-01
2022-05-16
0001589150
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-06-01
2022-06-09
0001589150
RGBP:AsOriginallyPresentedMember
2021-04-01
2021-06-30
0001589150
srt:RestatementAdjustmentMember
2021-04-01
2021-06-30
0001589150
RGBP:AsRestatedMember
2021-04-01
2021-06-30
0001589150
RGBP:AsOriginallyPresentedMember
2020-10-01
2021-06-30
0001589150
srt:RestatementAdjustmentMember
2020-10-01
2021-06-30
0001589150
RGBP:AsRestatedMember
2020-10-01
2021-06-30
0001589150
RGBP:AsOriginallyPresentedMember
2021-06-30
0001589150
srt:RestatementAdjustmentMember
2021-06-30
0001589150
RGBP:AsRestatedMember
2021-06-30
0001589150
us-gaap:SubsequentEventMember
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-07-01
2022-07-15
0001589150
us-gaap:SubsequentEventMember
us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember
2022-07-01
2022-07-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 10-Q
☒ QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended June 30, 2022
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from
Commission
File No. 333-191725
REGEN
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
Nevada |
45-5192997 |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
4700
Spring Street, St
304, La
Mesa, California 91942
(Address
of Principal Executive Offices)
619 722-5505
(Issuer’s
telephone number)
None
(Former
name, address and fiscal year, if changed since last report)
Check
whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12
months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Yes
☒ No
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☐
No ☒
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated
filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
☐ Large
accelerated filer |
☐ Accelerated
filer |
☐ Non-accelerated
filer |
☒ Smaller
reporting company |
|
☐ Emerging
Growth Company |
APPLICABLE
ONLY TO CORPORATE ISSUERS:
As
of July 17, 2022 Regen Biopharma, Inc. had 4,970,002,832 common
shares outstanding.
As
of July 17, 2022 Regen Biopharma, Inc. had 439,293,406 shares of Series A Preferred Stock outstanding.
As
of July 17, 2022 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.
As
of July 17, 2022 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.
As
of July 17, 2022 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):
Yes
☐ No ☒
PART
I - FINANCIAL INFORMATION
Item
1. - Financial Statements
| |
| | | |
| | |
REGEN
BIOPHARMA , INC. | |
| |
|
CONDENSED
CONSOLIDATED BALANCE SHEETS | |
| |
|
| |
| |
|
| |
As
of June 30, 2022 (unaudited) | |
As
of September 30, 2021 |
ASSETS | |
| |
|
CURRENT
ASSETS | |
| | | |
| | |
Cash | |
$ | 110,993 | | |
$ | 727,162 | |
Accounts
Receivable, Related Party | |
| 295,466 | | |
| 213,192 | |
Note
Receivable, Related Party | |
| 5,396 | | |
| 5,396 | |
Accrued
Interest Receivable | |
| 629 | | |
| 230 | |
Prepaid
Expenses | |
| 27,801 | | |
| 48,144 | |
Total
Current Assets | |
| 440,286 | | |
| 994,124 | |
| |
| | | |
| | |
OTHER
ASSETS | |
| | | |
| | |
Investment
Securities | |
| 26,828 | | |
| 198,006 | |
Investment
Securities, Related Party | |
| 222,580 | | |
| 19,969 | |
Total
Other Assets | |
| 249,408 | | |
| 217,975 | |
TOTAL
ASSETS | |
$ | 689,693 | | |
$ | 1,212,099 | |
LIABILITIES
AND STOCKHOLDERS' EQUITY | |
| | | |
| | |
Current
Liabilities: | |
| | | |
| | |
Accounts
payable | |
| 28,799 | | |
| 91,498 | |
Notes
Payable | |
| 227 | | |
| 1,429,179 | |
Accrued
payroll taxes | |
| 4,241 | | |
| 4,241 | |
Accrued
Interest | |
| 691,985 | | |
| 954,861 | |
Accrued
Rent | |
| | | |
| 0 | |
Accrued
Payroll | |
| 1,266,679 | | |
| 1,266,679 | |
Other
Accrued Expenses | |
| 41,423 | | |
| 41,423 | |
Bank
Overdraft | |
| 1,000 | | |
| 1,000 | |
Due
to Investor | |
| 20,000 | | |
| 20,000 | |
Unearned
Income | |
| 1,749,930 | | |
| 1,843,806 | |
Derivative
Liability | |
| 3,654,003 | | |
| 6,892,477 | |
Convertible
Notes Payable Less unamortized discount | |
| 1,571,090 | | |
| 2,131,311 | |
Convertible
Notes Payable, Related Parties Less unamortized discount | |
| 10,000 | | |
| 21,500 | |
Total
Current Liabilities | |
| 9,039,377 | | |
| 14,697,976 | |
Long
Term Liabilities: | |
| | | |
| | |
Convertible
Notes Payable, Related Parties Less unamortized discount | |
| | | |
| 0 | |
Total
Long Term Liabilities | |
| | | |
| | |
Total
Liabilities | |
| 9,039,377 | | |
| 14,697,976 | |
STOCKHOLDERS'
EQUITY (DEFICIT) | |
| | | |
| | |
Common
Stock ($.0001 par
value) 500,000,000 shares authorized; 5,800,000,000
authorized and 4,920,002,832
issued and outstanding as of June 30,2022
and 4,800,000,000 authorized
and 4,350,554,514 shares
issued and outstanding as of September 30 ,2021. | |
| 491,999 | | |
| 435,054 | |
Preferred
Stock, 0.0001 par
value, 800,000,000 authorized
as of June 30,2022 and September 30,2021 respectively | |
| | | |
| | |
Series
A Preferred; 300,000,000
authorized as of September 30,2021 and 540,000,000
authorized as of June 30, 2022 439,293,406
and 431,998,817
outstanding as of June 30,2022
and September 30, 2021 respectively | |
| 43,929 | | |
| 43,200 | |
Series
AA Preferred; $0.0001
par value 600,000
authorized and 50,000
and 50,000 outstanding
as of June 30,2022 and September 30,2021 respectively | |
| 5 | | |
| 5 | |
Series
M Preferred; $0.0001
par value 300,000,000
authorized and 44,000,000
outstanding as of September 30,2021 and 60,000,000
authorized and 44,000,000
outstanding as of June 30, 2022 | |
| 4,400 | | |
| 4,400 | |
Series
NC Preferred; $0.0001
par value 20,000 authorized
and 10 outstanding
as of September 30, 2021 and June 30,2022 respectively | |
| 1 | | |
| 1 | |
Additional
Paid in capital | |
| 11,200,998 | | |
| 8,644,037 | |
Contributed
Capital | |
| 736,326 | | |
| 736,326 | |
Retained
Earnings (Deficit) | |
| (20,827,342 | ) | |
| (23,348,900 | ) |
Total
Stockholders' Equity (Deficit) | |
| (8,349,684 | ) | |
| (13,485,877 | ) |
TOTAL
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) | |
$ | 689,693 | | |
$ | 1,212,099 | |
The
Accompanying Notes are an Integral Part of These Financial Statements
The
Accompanying Notes are an Integral Part of These Financial Statements
|
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
|
|
REGEN
BIOPHARMA , INC. |
|
Condensed
Consolidated Statement of Shareholder's Deficit |
|
(Unaudited) |
|
Nine
Months Ended June 30, 2021 (as restated) |
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
|
| |
| |
Series
A Preferred | |
Series
AA Preferred | |
Series
NC Preferred | |
Common | |
Series
M Preferred | |
| |
| |
|
|
| |
| |
Shares | |
Amount | |
Shares | |
Amount | |
Shares | |
Amount | |
Shares | |
Amount | |
Shares | |
Amount | |
Additional
Paid-in Capital | |
Retained
Earnings | |
Contributed
Capital | |
Total |
Balance
September 30, 2020 |
| |
Balance
September 30, 2020 | |
| 381,768,689 | | |
$ | 38,177 | | |
| 50,000 | | |
| 5 | | |
| — | | |
| — | | |
| 1,605,000,246 | | |
$ | 160,498 | | |
| 44,000,000 | | |
$ | 4,400 | | |
$ | 8,313,876 | | |
$ | (16,583,666 | ) | |
$ | 731,711 | | |
$(7,334,998) |
Shares
issued for Debt |
10/28/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 57,726,183 | | |
| 5,773 | | |
| | | |
| | | |
| (2,021 | ) | |
| | | |
| | | |
3,752 |
Shares
Issued For Interest |
10/28/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 22,339,663 | | |
| 2,234 | | |
| | | |
| | | |
| (782 | ) | |
| | | |
| | | |
1,452 |
Shares
issued for Debt |
11/6/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 60,007,919 | | |
| 6,001 | | |
| | | |
| | | |
| (2,101 | ) | |
| | | |
| | | |
3,900 |
Shares
Issued For Interest |
11/6/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 23,926,234 | | |
| 2,393 | | |
| | | |
| | | |
| (838 | ) | |
| | | |
| | | |
1,555 |
Shares
issued for Debt |
12/11/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 60,834,498 | | |
| 6,083 | | |
| | | |
| | | |
| 1,217 | | |
| | | |
| | | |
7,300 |
Shares
Issued For Interest |
12/11/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 26,185,501 | | |
| 2,619 | | |
| | | |
| | | |
| 523 | | |
| | | |
| | | |
3,142 |
Shares
issued for Debt |
12/16/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 3,300,000 | | |
| 330 | | |
| | | |
| | | |
| 99 | | |
| | | |
| | | |
429 |
Shares
Issued For Interest |
12/16/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,819,077 | | |
| 182 | | |
| | | |
| | | |
| 54 | | |
| | | |
| | | |
236 |
Shares
issued for Fees |
12/16/2020 | |
Shares
issued for Fees | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,228,077 | | |
| 123 | | |
| | | |
| | | |
| 36 | | |
| | | |
| | | |
159 |
Shares
issued for Debt |
12/16/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 62,003,571 | | |
| 6,200 | | |
| | | |
| | | |
| (2,170 | ) | |
| | | |
| | | |
4,030 |
Shares
Issued For Interest |
12/16/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 26,155,352 | | |
| 2,616 | | |
| | | |
| | | |
| (916 | ) | |
| | | |
| | | |
1,700 |
Shares
issued for Debt |
12/17/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 68,333,539 | | |
| 6,833 | | |
| | | |
| | | |
| 1,367 | | |
| | | |
| | | |
8,200 |
Shares
Issued For Interest |
12/17/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 14,883,378 | | |
| 1,488 | | |
| | | |
| | | |
| 212 | | |
| | | |
| | | |
1,700 |
Shares
issued for Debt |
12/17/2020 | |
Shares
issued for Debt | |
| 20,000,437 | | |
| 2,000 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 11,000 | | |
| | | |
| | | |
13,000 |
Shares
Issued For Interest |
12/17/2020 | |
Shares
Issued For Interest | |
| 12,378,732 | | |
| 1,238 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 6,808 | | |
| | | |
| | | |
8,046 |
Shares
issued for Debt |
12/23/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 88,888,889 | | |
| 8,889 | | |
| | | |
| | | |
| 7,111 | | |
| | | |
| | | |
16,000 |
Shares
Issued For Interest |
12/23/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 19,555,555 | | |
| 1,956 | | |
| | | |
| | | |
| 1,294 | | |
| | | |
| | | |
3,250 |
Shares
issued for Debt |
12/31/2020 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 82,004,603 | | |
| 8,200 | | |
| | | |
| | | |
| (2,870 | ) | |
| | | |
| | | |
5,330 |
Shares
Issued For Interest |
12/31/2020 | |
Shares
Issued For Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 35,832,781 | | |
| 3,583 | | |
| | | |
| | | |
| (1,254 | ) | |
| | | |
| | | |
2,329 |
Additions
to Contributed Capital Quarter ended 12/31/2020 |
| |
Additions
to Contributed Capital Quarter ended 12/31/2020 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,865 | | |
1,865 |
Net
Loss Quarter Ended December 31,2020 |
| |
Net
Loss Quarter Ended December 31,2020 | |
| | | |
| — | | |
| | | |
| — | | |
| | | |
| — | | |
| | | |
| | | |
| | | |
| — | | |
| | | |
| 1,666,367 | | |
| | | |
1,666,367 |
Balance
December 31, 2020 |
| |
Balance
December 31, 2020 | |
| 414,147,858 | | |
$ | 41,415 | | |
| 50,000 | | |
| 5 | | |
| — | | |
| — | | |
| 2,260,025,066 | | |
$ | 226,001 | | |
| 44,000,000 | | |
$ | 4,400 | | |
$ | 8,330,646 | | |
$ | (14,917,299 | ) | |
$ | 733,576 | | |
$(5,581,256) |
shares
issued for debt |
1/28/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 85,900,000 | | |
| 8,590 | | |
| | | |
| | | |
| (3,436 | ) | |
| | | |
| | | |
5,154 |
shares
issued for interest |
2/23/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 88,000,000 | | |
| 8,800 | | |
| | | |
| | | |
| (4,400 | ) | |
| | | |
| | | |
4,400 |
shares
issued for debt |
2/24/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 71,430,421 | | |
| 7,143 | | |
| | | |
| | | |
| 22,857 | | |
| | | |
| | | |
30,000 |
shares
issued for interest |
2/24/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 11,328,865 | | |
| 1,133 | | |
| | | |
| | | |
| 3,625 | | |
| | | |
| | | |
4,758 |
shares
issued for debt |
3/2/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 80,928,505 | | |
| 8,093 | | |
| | | |
| | | |
| (2,833 | ) | |
| | | |
| | | |
5,260 |
shares
issued for interest |
3/2/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 38,341,033 | | |
| 3,834 | | |
| | | |
| | | |
| (1,342 | ) | |
| | | |
| | | |
2,492 |
shares
issued for debt |
3/9/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 67,175,355 | | |
| 6,718 | | |
| | | |
| | | |
| (3,361 | ) | |
| | | |
| | | |
3,357 |
shares
issued for interest |
3/9/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 8,824,645 | | |
| 882 | | |
| | | |
| | | |
| (441 | ) | |
| | | |
| | | |
441 |
shares
issued for debt |
3/12/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 16,666,667 | | |
| 1,667 | | |
| | | |
| | | |
| (667 | ) | |
| | | |
| | | |
1,000 |
shares
issued for interest |
3/12/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 95,833,333 | | |
| 9,583 | | |
| | | |
| | | |
| (3,833 | ) | |
| | | |
| | | |
5,750 |
shares
issued for debt |
3/18/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 68,319,520 | | |
| 6,832 | | |
| | | |
| | | |
| (3,417 | ) | |
| | | |
| | | |
3,415 |
shares
issued for interest |
3/18/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,680,480 | | |
| 168 | | |
| | | |
| | | |
| (84 | ) | |
| | | |
| | | |
84 |
shares
issued for debt |
3/31/2021 | |
shares
issued for debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 38,519,260 | | |
| 3,852 | | |
| | | |
| | | |
| (1,927 | ) | |
| | | |
| | | |
1,925 |
shares
issued for interest |
3/31/2021 | |
shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,480,740 | | |
| 148 | | |
| | | |
| | | |
| (74 | ) | |
| | | |
| | | |
74 |
Additions
to Contributed Capital Quarter ended 3/31/2021 |
| |
Additions
to Contributed Capital Quarter ended 3/31/2021 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 250 | | |
250 |
Net
Income for the Quarter Ended March 31,2021 |
| |
Net
Income for the Quarter Ended March 31,2021 | |
| | | |
| — | | |
| | | |
| — | | |
| | | |
| — | | |
| | | |
| | | |
| — | | |
| — | | |
| | | |
| 442,183 | | |
| | | |
442,183 |
Balance
March 31, 2021 |
| |
Balance
March 31, 2021 | |
| 414,147,858 | | |
$ | 41,415 | | |
| 50,000 | | |
| 5 | | |
| 0 | | |
| 0 | | |
| 2,934,453,890 | | |
$ | 293,444 | | |
| 44,000,000 | | |
$ | 4,400 | | |
$ | 8,331,313 | | |
$ | (14,475,117 | ) | |
$ | 733,826 | | |
$(5,070,713) |
Shares
issued for Debt |
4/12/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 84,214,968 | | |
| 8,421 | | |
| | | |
| | | |
| (5,310 | ) | |
| | | |
| | | |
3,111 |
Shares
issued for interest |
4/12/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 785,032 | | |
| 79 | | |
| | | |
| | | |
| (30 | ) | |
| | | |
| | | |
49 |
Preferred
Shares issued for Services |
4/13/2021 | |
Preferred
Shares issued for Services | |
| | | |
| | | |
| | | |
| | | |
| 10000 | | |
| 1 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
1 |
Shares
issued for Debt |
4/13/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 26,389,990 | | |
| 2,639 | | |
| | | |
| | | |
| 16,361 | | |
| | | |
| | | |
19,000 |
Shares
issued for interest |
4/13/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 6,578,052 | | |
| 658 | | |
| | | |
| | | |
| 4,078 | | |
| | | |
| | | |
4,736 |
Shares
issued for Debt |
4/13/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 58,502,448 | | |
| 5,850 | | |
| | | |
| | | |
| (2,340 | ) | |
| | | |
| | | |
3,510 |
Shares
issued for interest |
4/13/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 25,134,385 | | |
| 2,513 | | |
| | | |
| | | |
| (1,005 | ) | |
| | | |
| | | |
1,508 |
Shares
issued for interest |
4/15/2021` | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 48,909,645 | | |
| 4,891 | | |
| | | |
| | | |
| (1,712 | ) | |
| | | |
| | | |
3,179 |
Shares
issued for Debt |
4/15/2021` | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 38,145,154 | | |
| 3,815 | | |
| | | |
| | | |
| (1,527 | ) | |
| | | |
| | | |
2,288 |
Shares
issued for interest |
4/15/2021` | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 11,336,846 | | |
| 1,134 | | |
| | | |
| | | |
| (454 | ) | |
| | | |
| | | |
680 |
Shares
issued for Debt |
4/15/2021` | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 89,950,579 | | |
| 8,995 | | |
| | | |
| | | |
| (4,757 | ) | |
| | | |
| | | |
4,238 |
Shares
issued for interest |
4/15/2021` | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 360,821 | | |
| 36 | | |
| | | |
| | | |
| (19 | ) | |
| | | |
| | | |
17 |
Shares
issued for Debt |
4/16/2021` | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 60,257,055 | | |
| 6,026 | | |
| | | |
| | | |
| 40,974 | | |
| | | |
| | | |
47,000 |
Shares
issued for interest |
4/16/2021` | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 10,498,830 | | |
| 1,050 | | |
| | | |
| | | |
| 7,139 | | |
| | | |
| | | |
8,189 |
Shares
issued for Debt |
4/21/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 126,423,649 | | |
| 12,642 | | |
| | | |
| | | |
| (4,987 | ) | |
| | | |
| | | |
7,655 |
Shares
issued for interest |
4/21/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 37,390,351 | | |
| 3,739 | | |
| | | |
| | | |
| (1,475 | ) | |
| | | |
| | | |
2,264 |
Shares
issued for Debt |
4/28/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 24,445,152 | | |
| 2,445 | | |
| | | |
| | | |
| 19,555 | | |
| | | |
| | | |
22,000 |
Shares
issued for interest |
4/28/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 4,339,015 | | |
| 434 | | |
| | | |
| | | |
| 3,471 | | |
| | | |
| | | |
3,905 |
Shares
issued for Debt |
5/3/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 21,792,903 | | |
| 2,179 | | |
| | | |
| | | |
| (763 | ) | |
| | | |
| | | |
1,416 |
Shares
issued for interest |
5/3/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 11,219,652 | | |
| 1,122 | | |
| | | |
| | | |
| (393 | ) | |
| | | |
| | | |
729 |
Shares
issued for Debt |
5/5/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 18,271,120 | | |
| 1,827 | | |
| | | |
| | | |
| (640 | ) | |
| | | |
| | | |
1,187 |
Shares
issued for interest |
5/5/2021 | |
Shares
issued for interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 9,481,896 | | |
| 948 | | |
| | | |
| | | |
| (332 | ) | |
| | | |
| | | |
616 |
Shares
issued for Debt |
5/18/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 33,772,000 | | |
| 3,377 | | |
| | | |
| | | |
| (1,351 | ) | |
| | | |
| | | |
2,026 |
Contributed
Capital Quarter Ended June 30, 2021 |
| |
Contributed
Capital Quarter Ended June 30, 2021 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 2,500 | | |
2,500 |
Net
Loss for the Quarter Ended June 30,2021 |
| |
Net
Loss for the Quarter Ended June 30,2021 | |
| | | |
| — | | |
| | | |
| — | | |
| | | |
| — | | |
| | | |
| | | |
| | | |
| — | | |
| | | |
| (7,489,115 | ) | |
| | | |
(7,489,115) |
Balance
June 30, 2021 |
| |
Balance
June 30, 2021 | |
| 414,147,858 | | |
$ | 41,415 | | |
| 50,000 | | |
$ | 5 | | |
| 10,000 | | |
$ | 1 | | |
| 3,780,195,788 | | |
$ | 378,018 | | |
| 44,000,000 | | |
$ | 4,400 | | |
$ | 8,392,382 | | |
$ | (21,964,232 | ) | |
$ | 736,326 | | |
$(12,411,685) |
Balance
September 30, 2021 |
| |
Balance
September 30, 2021 | |
| 431,998,817 | | |
$ | 43,200 | | |
| 50,000 | | |
$ | 5 | | |
| 10,000 | | |
$ | 1 | | |
| 4,350,554,514 | | |
$ | 435,054 | | |
| 44,000,000 | | |
$ | 4,400 | | |
$ | 8,644,037 | | |
$ | (23,348,900 | ) | |
$ | 736,326 | | |
$(13,485,877) |
Shares
issued for Debt |
10/1/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 10,000,000 | | |
| 1,000 | | |
| | | |
| | | |
| 99,000 | | |
| | | |
| | | |
100,000 |
Shares
issued for Interest |
10/1/2021 | |
Shares
issued for Interest | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 2,666,200 | | |
| 267 | | |
| | | |
| | | |
| 26,395 | | |
| | | |
| | | |
26,662 |
Shares
issued for Debt |
10/1/2021 | |
Shares
issued for Debt | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 10,000,000 | | |
| 1,000 | | |
| | | |
| | | |
| 99,000 | | |
| | | |
| | | |
100,000 |
Shares
issued for Interest |
10/1/2021 | |
Shares
issued for Interest | |
| | | |
| | | |
| | | |
| | | |
|